TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17263861
Drug: Rectal Voltarol
Normalized name: totarol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Voltarol
Study: 12905468
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg)
Study: 11529382
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg/day) for 10 days after initial ceftriaxone (75 mg/kg/day)
Study: 11529382
Drug: Ceftriaxone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (75 mg/kg/day)
Study: 11529382
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg/day)
Study: 8142127
Drug: 10% sucralfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucralfate suspension (Group 2)
Study: 8142127
Drug: Antacid containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid containing sodium alginate (Group 1)
Study: 3203571
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of fructose
Study: 27620342
Drug: EXER +
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXER + CBT (exercise program plus cognitive-behavioral therapy)
Study: 27620342
Drug: CONTROL (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL (routine treatment)
Study: 25780837
Drug: Rural patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rural patients receiving surgical treatment for hip osteoarthritis
Study: 25780837
Drug: Urban patients
Normalized name: Geum urbanum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urban patients receiving surgical treatment for hip osteoarthritis
Study: 24326918
Drug: Rubric exam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubric exam preparation group
Study: 24326918
Drug: Nonrubric exam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrubric exam preparation group
Study: 21353262
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (beer, ∼26 g alcohol)
Study: 19767761
Drug: 16 G-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 G-needle
Study: 19767761
Drug: 18 G-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 G-needle
Study: 9118185
Drug: F dentifrice
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F dentifrice + F lozenges (0.25 mg F x 6/day)
Study: 9118185
Drug: F dentifrice
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F dentifrice + F chewing-gum (0.25 mg F x 6/day)
Study: 3538481
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 mg thrice daily)
Study: 25881320
Drug: Bravecto™ (fluralaner),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bravecto™ (fluralaner), 25 mg/kg body weight, single oral administration
Study: 25881320
Drug: Advocate® (imidacloprid/moxidectin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advocate® (imidacloprid/moxidectin), 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight, topical administration on three occasions at 28-day intervals
Study: 23741066
Drug: Quisinostat (JNJ-26481585)
Normalized name: Quisinostat
DrugBank: Quisinostat (DB12985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quisinostat (JNJ-26481585) administered orally, once daily in three weekly cycles, with doses ranging from 2-12 mg for continuous dosing and 6-19 mg for intermittent dosing schedules.
Study: 23741066
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing schedules (four days on/three days off; every Monday, Wednesday, Friday; every Monday and Thursday)
Study: 25503082
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (100-250 mg bid)
Study: 21162697
Drug: Open-label titration
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label titration phase (Tapentadol ER)
Study: 18971855
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% ciclosporin A (CsA) for 3 months after surgery
Study: 18971855
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard topical therapy)
Study: 12941721
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 units subcutaneous injection once daily)
Study: 12941721
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological saline equivalent volume once daily)
Study: 11019420
Drug: Trimetazidine (TMS)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMS) 60 mg
Study: 11019420
Drug: Trimetazidine (TMS)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMS) added to selected antianginal drugs
Study: 8618579
Drug: Aerosolized synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized synthetic surfactant (13.5 mg of dipalmitoylphosphatidylcholine per milliliter) administered continuously for up to five days
Study: 8618579
Drug: Placebo (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.45 percent saline) administered continuously for up to five days
Study: 1570391
Drug: No patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patches
Study: 2802118
Drug: Diazepam (0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.28 mg/kg)
Study: 26749219
Drug: HYD 30
Normalized name: sod/pot/Cl/cit/Zn/mag/carbohyd 305 mg-175 mg-70 mg-2.5 gram-2 mg-40 mg-9 gram ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD 30 mg once daily
Study: 26749219
Drug: HYD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD 20 to 120 mg
Study: 26749219
Drug: HYD 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD 120 mg once daily
Study: 26749219
Drug: HYD 30
Normalized name: sod/pot/Cl/cit/Zn/mag/carbohyd 305 mg-175 mg-70 mg-2.5 gram-2 mg-40 mg-9 gram ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD 30 mg
Study: 25069991
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (o‐CEE), 0.45 mg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Study: 25069991
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (t‐E2), 50 mcg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Study: 23179383
Drug: D +
Normalized name: Liver Desiccated + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: D + 3 progesterone treatment
Study: 23179383
Drug: D +
Normalized name: Liver Desiccated + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: D + 4 progesterone treatment
Study: 19732051
Drug: Tadalafil (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (2.5, 5, 10, 20 mg)
Study: 18044196
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy combined with other Cognitive‐Behavioral Therapy (CBT) components
Study: 9489976
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mibefradil once daily for 2 weeks
Study: 9489976
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mibefradil once daily for 2 additional weeks
Study: 31883845
Drug: Brodalumab 140
Normalized name: brodalumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 140 mg (n = 46)
Study: 31883845
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg (n = 41)
Study: 28012190
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid patches (Callívoro Marthand®)
Study: 23329886
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (tidal volume 8 ml/kg, frequency 12/min)
Study: 23329886
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (tidal volume 6 ml/kg, frequency 16/min)
Study: 21262922
Drug: Postoperative antibacterials
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibacterials (treatment indication)
Study: 18199726
Drug: Buccal mucosa
Normalized name: Diazepam 5 MG Buccal mucosa Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mucosa cells (BMC) harvested at baseline and 3 days after baseline.
Study: 18199726
Drug: Leukocytes collected
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytes collected in heparin and EDTA.
Study: 16600934
Drug: Glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.5 g . kg(‐1) . d(‐1))
Study: 16600934
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture (0.8 g . kg(‐1) . d(‐1))
Study: 15000437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Glyburide and Metformin
Study: 11345687
Drug: Ketoprofen lysinate
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen lysinate solution (160 mg in 100 ml, twice a day for seven days)
Study: 11345687
Drug: Benzidamine hydrochloride
Normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzidamine hydrochloride (15 ml, twice a day for seven days)
Study: 8868980
Drug: Pimobendan 5
Normalized name: pimobendan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 5 mg daily
Study: 1729854
Drug: Pimobendan 10
Normalized name: pimobendan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 10 mg daily
Study: 30537550
Drug: Continuous TKI
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous TKI with chemotherapy (nontransplant arm)
Study: 29898217
Drug: Topical ozenoxacin
Normalized name: ozenoxacin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozenoxacin cream 1%
Study: 22150098
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (8 ounces daily for 1 month)
Study: 22150098
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (8 ounces daily for 1 month)
Study: 20886510
Drug: CoQ(10) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) treatment (1200 mg/day for 60 days)
Study: 17302514
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous iron sucrose
Study: 17302514
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=5) without iron treatment
Study: 10435727
Drug: Busulphan at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan at 600 mg/m2 with cyclophosphamide alone (Group B)
Study: 10435727
Drug: Busulphan at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan at 16 mg/kg with cyclophosphamide and ATG (Group A)
Study: 10435727
Drug: Busulphan at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan at 600 mg/m2 (Group B)
Study: 10435727
Drug: Busulphan at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan at 16 mg/kg (Group A)
Study: 8574032
Drug: Gd zeolite
Normalized name: zeolite A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd zeolite oral suspension (250 to 1500 mL; 6 to 60 micrograms of Gd+3/mL) administered before and after MRI
Study: 8574032
Drug: Gd zeolite
Normalized name: zeolite A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd zeolite oral suspension
Study: 7428408
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mianserin
Study: 375686
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg mianserin
Study: 7428408
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sustained-release amitriptyline
Study: 19827484
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied hydrogel containing 0.5% morphine plus subcutaneous placebo infusion
Study: 19827484
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel plus subcutaneous infusion of 5mg morphine
Study: 19827484
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel plus subcutaneous placebo infusion
Study: 9626795
Drug: Carboplatin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (600 mg/m2) and Cyclophosphamide (1,500 mg/m2) with filgrastim
Study: 9626795
Drug: Carboplatin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (300 mg/m2) and Cyclophosphamide (600 mg/m2) without filgrastim
Study: 9626795
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and Cyclophosphamide at 2.5 times standard dose with filgrastim
Study: 9626795
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and Cyclophosphamide at standard dose without filgrastim
Study: 9626795
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and Cyclophosphamide at 2.5 times standard dose
Study: 8055283
Drug: Systemic brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic brachytherapy with radiolabeled antibodies
Study: 30772342
Drug: Diclofenac suppositories
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppositories (50 mg) + Sublingual isosorbide dinitrate (5 mg)
Study: 30772342
Drug: Diclofenac suppositories
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppositories (50 mg)
Study: 25801162
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.3 mg/kg) with midazolam (0.02 mg/kg) and fentanyl (1 μg/kg)
Study: 25801162
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg/kg) and fentanyl (1 μg/kg) with placebo (0.9% sodium chloride)
Study: 23686563
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day elemental iron supplements
Study: 23686563
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day elemental iron + 500 mg/day ascorbic acid
Study: 22080318
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat chocolate milk (1 g carbohydrate per kg body weight)
Study: 17407641
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g paracetamol plus 130 mg caffeine
Study: 9476036
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g paracetamol alone
Study: 17407641
Drug: 130 mg
Normalized name: pectin 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 mg caffeine alone
Study: 9647338
Drug: tolrestat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolrestat (200 mg a day)
Study: 2582720
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion at a rate of 2 i.u./h for 1 h, followed by 4 i.u./h for a further hour
Study: 29319721
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion
Study: 23189924
Drug: Negotiated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negotiated treatment plan
Study: 23189924
Drug: No negotiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: No negotiated treatment plan
Study: 23189924
Drug: Negotiated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negotiated treatment plan at fewer than three time points
Study: 21241290
Drug: MgCl(2) 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgCl(2) 2.5 g daily
Study: 21241290
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive solution)
Study: 18055171
Drug: Systemic anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic anticoagulation with intravenous heparin
Study: 9706914
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (control)
Study: 24677033
Drug: HQK-1001 (2,2-dimethylbutyrate)
Normalized name: 2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 (2,2-dimethylbutyrate) at 15 mg/kg twice daily for 48 weeks
Study: 15339465
Drug: Xiangdan Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiangdan Injection plus standard treatment for coronary heart disease
Study: 15339465
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for coronary heart disease (Control)
Study: 9817278
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of MCV chemotherapy before concurrent cisplatin and radiation therapy (arm 1, n=61)
Study: 9817278
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy (arm 2, n=62)
Study: 7654489
Drug: Intravenous dexfenfluramine
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexfenfluramine (d-F) 15.5 mg base infused over 3 h
Study: 7654489
Drug: Oral dexfenfluramine
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexfenfluramine (d-F) 25.9 mg base in capsules
Study: 7654489
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral dexfenfluramine (d-F)
Study: 30864006
Drug: PPB +
Normalized name: Piperacillin plus Tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPB + IRLA (3.0 mL of 2% lidocaine injected at the bilateral pelvic plexus)
Study: 30864006
Drug: PNB +
Normalized name: PNB
DrugBank: P-nitrobiphenyl (DB12300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNB + IRLA (3.0 mL of 2% lidocaine injected at both periprostatic nerves)
Study: 25847131
Drug: Alteplase 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 0.1 mg/kg twice a day on days 1 and 3 or days 2 and 4
Study: 23667063
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m(2)
Study: 16176939
Drug: DMPA-SC 104
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA-SC 104 (104 mg/0.65 ml every 3 months)
Study: 16176939
Drug: Leuprolide (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Study: 9170576
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (goserelin acetate depot 3.6 mg subcutaneously every 4 weeks)
Study: 9170576
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy (goserelin acetate depot 3.6 mg subcutaneously and cyclophosphamide 1000 mg/m2 intravenously every 4 weeks)
Study: 29525541
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy
Study: 1951075
Drug: Low-dose sotalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sotalol (40 mg every 6 hours for 6 days)
Study: 7230984
Drug: Oral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobial bowel preparation with metronidazole and kanamycin
Study: 7230984
Drug: Parenteral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotic prophylaxis with metronidazole and kanamycin
Study: 31919035
Drug: Mini-goal games
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-goal games (MG)
Study: 25875795
Drug: Single-step treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-step treatment
Study: 25875795
Drug: 2-step treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-step treatment
Study: 23571173
Drug: Two-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose inactivated hepatitis A vaccine (Healive(®))
Study: 23571173
Drug: One-dose inactivated
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose inactivated hepatitis A vaccine (Healive(®))
Study: 23571173
Drug: Attenuated vaccine
Normalized name: Chikungunya live attenuated vaccine, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated vaccine B
Study: 23571173
Drug: Attenuated vaccine
Normalized name: Chikungunya live attenuated vaccine, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated vaccine C
Study: 23571173
Drug: Attenuated vaccine
Normalized name: Chikungunya live attenuated vaccine, 0.5 mL, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated vaccine A
Study: 21819749
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of i.v. dexamethasone preoperatively and again after 24 and 48 hours after surgery
Study: 21819749
Drug: Three pseudoephedrine
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three pseudoephedrine tablets (60 mg) per day for 1 week
Study: 21819749
Drug: Three pseudoephedrine
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three pseudoephedrine tablets (60 mg) per day for 2 weeks